Stramsen Biotech Inc, a plant-based biopharmaceutical company, has announced that it has signed a binding agreement with GEM Global Yield LLC SCS (GGY), part of GEM, a Luxembourg-based private alternative investment group as its lead investor, for a USD 25 million share subscription facility to be funded annually over a 36-month term following a public listing of the Stramsen's common stock.

The funds secured through the share subscription facility will be strategically utilised to accelerate Stramsen's growth trajectory and propel clinical development and recruitment of seasoned management and scientific teams.

Stramsen will control the timing and maximum amount of drawdowns under this facility and has no minimum drawdown obligation.

Scott Villwock, President and Chief Executive Officer of Stramsen Biotech said, “This commitment from GEM validates Stramsen Biotech's vision of providing nature-based, sustainable, and affordable health solutions with minimal side effects to patients worldwide.”

The USD 25 million facility from GGY will significantly support Stramsen Biotech Inc.'s ambitious growth plans and empower the company to accelerate global expansion initiatives, positioning Stramsen as a leader in plant-based biopharmaceuticals, the company said in a statement.

The fund will also help the company to prepare for a prospectus submission and ultimately pursue an Initial Public Offering (IPO), enhancing its financial position and market visibility. It plans to invest in the research and development of 33 innovative drug candidates, leveraging a natural plant-based approach to transform patient lives. As part of its pipeline advancement, the company will initiate the submission of multiple Investigational New Drug (IND) applications with the Food and Drug Administration (FDA) to move closer to clinical trials. Additionally, it seeks to establish a distinguished Scientific Advisory Board and expand its team of seasoned scientists, reinforcing its expertise and leadership in the industry.